Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer

Table 1

Demographics, clinical features, and risk stratification of studied patients.

	Patients who answered only early survey	Patients who answered both surveys
Participants ()	110	61
Females (%)	91,8	96,7	ns
Age at diagnosis (years ± SD)	43,4 ± 13,8	41,4 ± 14,5	ns
Type of surgery
Total thyroidectomy (TT) (%)	76,4	68,9	ns
TT + lymph node Resection (%)	23,6	31,1	ns
ATA classification at diagnosis
Low risk (%)	54,5	52,5	ns
Intermediate risk (%)	45,5	47,5	ns
High risk (%)	0	0	ns
Time to survey
First survey (months ± SD)	2.5 (0.5–5.8)		na
Second survey (months ± SD)	—	11.5 (6–18.6)	na
Radioiodine therapy
Patients treated with RAI (%)	78,2	80,3	ns
Median RAI dosage (range)	100 (30–150)	100 (30–150)	ns
ATA low risk patients with RAI (%)	63,3	62,5	ns
ATA intermediate risk patients with RAI (%)	96	100	ns